Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Annals of oncology: official journal of the European Society for Medical Oncology / ESMO [Ann Oncol] NLMUID: 9007735"" wg kryterium: JN


Tytuł :
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.
Autorzy :
Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; University of Melbourne, Melbourne, Victoria, Australia.
Huang HC; Decipher Biosciences, San Diego, CA, USA.
Wang V; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Chen YH; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Feng F; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Den R; Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Attard G; University College London Cancer Institute, London, United Kingdom.
Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tran PT; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Spratt DE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Dittamore R; Decipher Biosciences, San Diego, CA, USA.
Davicioni E; Decipher Biosciences, San Diego, CA, USA.
Liu G; University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
DiPaola R; University of Kentucky Medical Center, Lexington, KY, USA.
Carducci MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 12. Date of Electronic Publication: 2021 Jun 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
Autorzy :
Bardia A; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Loirat D; Medical Oncology Department and D3i, Institut Curie, Paris, France.
Oliveira M; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Kalinsky K; Columbia University Irving Medical Center, New York, NY, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Zelnak A; Northside Hospital, Atlanta, GA, USA.
Aftimos P; Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Dalenc F; Institut Claudius Regaud, Toulouse, France.
Sardesai S; The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Sharma P; University of Kansas Medical Center - Westwood, KS, USA.
Recalde S; Institut Catala d'Oncologia Hospitalet, Barcelona, Spain.
Gil EC; Hospital Universitario 12 de Octubre, Madrid, Spain.
Traina T; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
Cortes J; International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Spain.
Tsai M; VPCI Oncology Research, Minneapolis, MN, USA.
Vahdat L; MSK-Norwalk Hospital Partnership, Norwalk, CT, USA.
Diéras V; Centre Eugène Marquis, Rennes, France.
Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
Goldenberg DM; Immunomedics, Inc., Morris Plains, NJ, USA; Center for Molecular Medicine and Immunology, Mendham, NJ, USA.
Hong Q; Immunomedics, Inc., Morris Plains, NJ, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, NJ, USA.
Olivo M; Immunomedics, Inc., Morris Plains, NJ, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, NJ, USA.
Itri LM; Immunomedics, Inc., Morris Plains, NJ, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, NJ, USA.
Hurvitz SA; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 08. Date of Electronic Publication: 2021 Jun 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Autorzy :
Jhaveri KL; Department of Medicine, Memorial Sloan-Kettering Center, New York, USA. Electronic address: .
Wang XV; Biostatistics, E-A Biostatistical Center, Boston, USA.
Makker V; Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
Luoh SW; Knight Cancer Institute, Oregon Health Science University, Portland, USA.
Mitchell EP; Medical Oncology, Thomas Jefferson University, Philadelphia, USA.
Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
Sharon E; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA.
Gray RJ; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA.
Li S; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA.
McShane LM; Biometric Research Branch, National Cancer Institute, Bethesda, USA.
Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, USA.
Patton D; Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda, USA.
Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA.
Hamilton SR; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
Arteaga CL; Department of Internal Medicine, University of Texas Southwestern, Dallas, USA.
Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
O'Dwyer PJ; University of Pennsylvania, Philadelphia, USA.
Chen AP; CTEP, National Cancer Institute, Bethesda, USA.
Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, USA.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 04. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji :
Published Erratum
Tytuł :
Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
Autorzy :
Reck M; Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany. Electronic address: .
Carbone DP; James Thoracic Oncology Center, The Ohio State University, Columbus, OH; Department of Medicine, Section Hematology Oncology.
Garassino M; The University of Chicago, Chicago, IL.
Barlesi F; Aix Marseille University, Marseille, France; Gustave Roussy Cancer Campus, Villejuif, France.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 02. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
Autorzy :
Mirza MR; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: .
Coleman RL; Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
González-Martín A; Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
Moore KN; Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, USA.
Colombo N; Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy.
Ray-Coquard I; Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G.Pascale, Napoli, Italy.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 02. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Published Erratum
Tytuł :
Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231].
Autorzy :
Mandelker D; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: .
Donoghue M; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Talukdar S; Department of Clinical Genetics, St George's University of London, London, UK.
Bandlamudi C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Srinivasan P; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Vivek M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
Jezdic S; European Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
Hanson H; Department of Clinical Genetics, St George's University of London, London, UK.
Snape K; Department of Clinical Genetics, St George's University of London, London, UK.
Kulkarni A; Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK.
Hawkes L; Department of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Douillard JY; European Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
Wallace SE; Department of Health Sciences, University of Leicester, Leicester, UK.
Rial-Sebbag E; University of Toulouse, Toulouse, France.
Meric-Bersntam F; Department of Investigational CancerTherapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
George A; Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Chubb D; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Loveday C; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.
Berger MF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Taylor BS; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Clinical Genetics, St George's University of London, London, UK; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
Turnbull C; Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK; William Harvey Research Institute, Queen Mary University of London, London, UK; Public Health England, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun 02. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Published Erratum
Tytuł :
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Autorzy :
Jayaram A; University College London Cancer Institute, London, UK.
Wingate A; University College London Cancer Institute, London, UK.
Wetterskog D; University College London Cancer Institute, London, UK.
Wheeler G; University College London Cancer Institute, London, UK.
Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, USA.
Jones R; University of Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, UK.
Berruti A; University of Brescia, Spedali Civili Hospital, Brescia, Italy.
Lefresne F; Janssen-Cilag, France.
Lahaye M; Janssen-Cilag, France.
Thomas S; Janssen Research and Development, LLC, Spring House, Pennsylvania, USA.
Gormley M; Janssen Research and Development, LLC, Spring House, Pennsylvania, USA.
Meacham F; Resolution BioScience, Inc., Kirkland, USA.
Garg K; Resolution BioScience, Inc., Kirkland, USA.
Lim LP; Resolution BioScience, Inc., Kirkland, USA.
Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Tombal B; Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium.
Ricci D; Janssen Research and Development, LLC, Spring House, Pennsylvania, USA.
Attard G; University College London Cancer Institute, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 726-735. Date of Electronic Publication: 2021 Mar 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Corrigendum to 'Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Annals of Oncology Volume 31, Issue 6, June 2020, Pages 697-712].
Autorzy :
Heuser M; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Ofran Y; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Boissel N; Department of Hematology, AP-HP, Saint-Louis Hospital, Paris, France; Université de Paris, Paris, France.
Brunet Mauri S; Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Jose Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.
Janssen J; Department of Hematology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.
Wierzbowska A; Department of Hematology, Medical University of Lodz, Lodz, Poland; Copernicus Memorial Hospital, Lodz, Poland.
Buske C; Comprehensive Cancer Center, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
Pokaż więcej
Corporate Authors :
ESMO Guidelines Committee. Electronic address:
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 821. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Published Erratum
Tytuł :
IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy.
Autorzy :
Gutzmer R; Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden/Ruhr-University Bochum, Minden, Germany. Electronic address: .
Sibaud V; Cancer University Institute, Toulouse Oncopole, Toulouse, France.
Hassel JC; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 696-697. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji :
Editorial; Comment
Opinia redakcyjna
Tytuł :
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate.
Autorzy :
Loriot Y; Department of Cancer Medicine and INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: .
Fizazi K; Department of Cancer Medicine and INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 694-695. Date of Electronic Publication: 2021 Apr 08.
Typ publikacji :
Editorial; Comment
Opinia redakcyjna
Tytuł :
Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women.
Autorzy :
Yue Y; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA.
Hur J; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA. Electronic address: .
Cao Y; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, USA; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, USA.
Tabung FK; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, USA.
Wang M; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Wu K; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA.
Song M; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; Harvard Medical School, Boston, USA.
Zhang X; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Liu Y; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital, Boston, USA.
Meyerhardt JA; Evidence-Based Chinese Medicine, School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Ng K; Evidence-Based Chinese Medicine, School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Smith-Warner SA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA.
Willett WC; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Giovannucci E; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 778-786. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Colorectal Neoplasms*/epidemiology
Colorectal Neoplasms*/etiology
Diet*
Adult ; Cohort Studies ; Female ; Humans ; Life Style ; Middle Aged ; Prospective Studies ; Risk Factors
Czasopismo naukowe
Tytuł :
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Autorzy :
Rawson RV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; NSW Health Pathology, Sydney, Australia.
Adhikari C; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; NSW Health Pathology, Sydney, Australia.
Bierman C; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Shklovskaya E; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
Rozeman EA; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
van Akkooi ACJ; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Gonzalez M; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Guminski AD; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Tetzlaff MT; Department of Pathology, Dermatopathology and Oral Pathology Unit, The University of California, San Francisco, San Francisco, USA; Department of Dermatology, Dermatopathology and Oral Pathology Unit, The University of California, San Francisco, San Francisco, USA.
Stretch JR; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Eriksson H; Theme Cancer, Skin Cancer Center/Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
van Thienen JV; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Wouters MW; The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Haanen JBAG; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Klop WMC; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Zuur CL; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Houdt WJ; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Rizos H; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Blank CU; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
van de Wiel BA; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Departments of Tissue Pathology and Diagnostic Oncology, Sydney, Australia; Department of Melanoma Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia; NSW Health Pathology, Sydney, Australia. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 766-777. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Autorzy :
Grivas P; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA. Electronic address: .
Khaki AR; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA; Stanford University, Stanford, USA.
Wise-Draper TM; University of Cincinnati Cancer Center, Cincinnati, USA.
French B; Vanderbilt University Medical Center, Nashville, USA.
Hennessy C; Vanderbilt University Medical Center, Nashville, USA.
Hsu CY; Vanderbilt University Medical Center, Nashville, USA.
Shyr Y; Vanderbilt University Medical Center, Nashville, USA.
Li X; Vanderbilt University School of Medicine, Nashville, USA.
Choueiri TK; Dana-Farber Cancer Institute, Boston, USA.
Painter CA; Broad Institute, Cancer Program, Cambridge, USA.
Peters S; Lausanne University, Lausanne, Switzerland.
Rini BI; Vanderbilt University Medical Center, Nashville, USA.
Thompson MA; Advocate Aurora Health, Milwaukee, USA.
Mishra S; Vanderbilt University Medical Center, Nashville, USA.
Rivera DR; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, USA.
Acoba JD; University of Hawaii Cancer Center, Honolulu, USA.
Abidi MZ; University of Colorado School of Medicine, Aurora, USA.
Bakouny Z; Dana-Farber Cancer Institute, Boston, USA.
Bashir B; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
Bekaii-Saab T; Mayo Clinic Cancer Center, Phoenix, USA.
Berg S; Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, USA.
Bernicker EH; Houston Methodist Cancer Center, Houston, USA.
Bilen MA; Winship Cancer Institute of Emory University, Atlanta, USA.
Bindal P; Beth Israel Deaconess Medical Center, Boston, USA.
Bishnoi R; University of Florida, Gainesville, USA.
Bouganim N; McGill University Health Centre, Montréal, Canada.
Bowles DW; University of Colorado School of Medicine, Aurora, USA.
Cabal A; University of California San Diego, Moores Cancer Center, La Jolla, USA.
Caimi PF; University Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
Chism DD; Thompson Cancer Survival Center, Knoxville, USA.
Crowell J; St. Elizabeth Healthcare, Edgewood, USA.
Curran C; Dana-Farber Cancer Institute, Boston, USA.
Desai A; Mayo Clinic Cancer Center, Rochester, USA.
Dixon B; St. Elizabeth Healthcare, Edgewood, USA.
Doroshow DB; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Durbin EB; Markey Cancer Center, University of Kentucky, Lexington, USA.
Elkrief A; McGill University Health Centre, Montréal, Canada.
Farmakiotis D; The Warren Alpert Medical School of Brown University, Providence, USA.
Fazio A; Tufts Medical Center Cancer Center, Boston and Stoneham, USA.
Fecher LA; University of Michigan Rogel Cancer Center, Ann Arbor, USA.
Flora DB; St. Elizabeth Healthcare, Edgewood, USA.
Friese CR; University of Michigan Rogel Cancer Center, Ann Arbor, USA.
Fu J; Tufts Medical Center Cancer Center, Boston and Stoneham, USA.
Gadgeel SM; Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Gill DM; Intermountain Healthcare, Salt Lake City, USA.
Glover MJ; Stanford University, Stanford, USA.
Goyal S; George Washington University, Washington DC, USA.
Grover P; University of Cincinnati Cancer Center, Cincinnati, USA.
Gulati S; University of Cincinnati Cancer Center, Cincinnati, USA.
Gupta S; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Halabi S; Duke University, Durham, USA.
Halfdanarson TR; Mayo Clinic Cancer Center, Rochester, USA.
Halmos B; Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
Hausrath DJ; Vanderbilt University School of Medicine, Nashville, USA.
Hawley JE; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA.
Hsu E; Hartford HealthCare, Hartford, USA; University of Connecticut, Farmington, USA.
Huynh-Le M; George Washington University, Washington DC, USA.
Hwang C; Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
Jani C; Mount Auburn Hospital, Cambridge, USA.
Jayaraj A; Hartford HealthCare, Hartford, USA.
Johnson DB; Vanderbilt University Medical Center, Nashville, USA.
Kasi A; University of Kansas Medical Center, Kansas City, USA.
Khan H; The Warren Alpert Medical School of Brown University, Providence, USA.
Koshkin VS; University of California, San Francisco, San Francisco, USA.
Kuderer NM; Advanced Cancer Research Group, LLC, Kirkland, USA.
Kwon DH; University of California, San Francisco, San Francisco, USA.
Lammers PE; Baptist Cancer Center, Memphis, USA.
Li A; Baylor College of Medicine, Houston, USA.
Loaiza-Bonilla A; Cancer Treatment Centers of America, Philadelphia, USA.
Low CA; Intermountain Healthcare, Salt Lake City, USA.
Lustberg MB; The Ohio State University, Columbus, USA.
Lyman GH; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
McKay RR; University of California San Diego, Moores Cancer Center, La Jolla, USA.
McNair C; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
Menon H; Penn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, Hershey, USA.
Mesa RA; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
Mico V; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
Mundt D; Advocate Aurora Health, Milwaukee, USA.
Nagaraj G; Loma Linda University Cancer Center, Loma Linda, USA.
Nakasone ES; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
Nakayama J; Case Western Reserve University, Cleveland, USA; University Hospitals Cleveland Medical Center, Cleveland, USA.
Nizam A; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Nock NL; University Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
Park C; University of Cincinnati Cancer Center, Cincinnati, USA.
Patel JM; Beth Israel Deaconess Medical Center, Boston, USA.
Patel KG; University of California Davis Comprehensive Cancer Center, Sacramento, USA.
Peddi P; Willis-Knighton Cancer Center, Shreveport, USA.
Pennell NA; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Piper-Vallillo AJ; Beth Israel Deaconess Medical Center, Boston, USA.
Puc M; Virtua Health, Marlton, USA.
Ravindranathan D; Winship Cancer Institute of Emory University, Atlanta, USA.
Reeves ME; Loma Linda University Cancer Center, Loma Linda, USA.
Reuben DY; Medical University of South Carolina, Charleston, USA.
Rosenstein L; Gunderson Health System, La Crosse, USA.
Rosovsky RP; Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Rubinstein SM; University of North Carolina, Chapel Hill, USA.
Salazar M; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
Schmidt AL; Dana-Farber Cancer Institute, Boston, USA.
Schwartz GK; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA.
Shah MR; Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
Shah SA; Stanford University, Stanford, USA.
Shah C; University of Florida, Gainesville, USA.
Shaya JA; University of California San Diego, Moores Cancer Center, La Jolla, USA.
Singh SRK; Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
Smits M; ThedaCare Regional Cancer Center, Appleton, USA.
Stockerl-Goldstein KE; Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA.
Stover DG; The Ohio State University, Columbus, USA.
Streckfuss M; Advocate Aurora Health, Milwaukee, USA.
Subbiah S; Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, USA.
Tachiki L; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
Tadesse E; Advocate Aurora Health, Milwaukee, USA.
Thakkar A; Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
Tucker MD; Vanderbilt University Medical Center, Nashville, USA.
Verma AK; Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
Vinh DC; McGill University Health Centre, Montréal, Canada.
Weiss M; ThedaCare Regional Cancer Center, Appleton, USA.
Wu JT; Stanford University, Stanford, USA.
Wulff-Burchfield E; Mount Auburn Hospital, Cambridge, USA.
Xie Z; Mayo Clinic Cancer Center, Rochester, USA.
Yu PP; Hartford HealthCare, Hartford, USA.
Zhang T; Duke University, Durham, USA.
Zhou AY; Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA.
Zhu H; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Zubiri L; Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Shah DP; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
Warner JL; Vanderbilt University Medical Center, Nashville, USA.
Lopes G; University of Miami/Sylvester Comprehensive Cancer Center, Miami, USA.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 787-800. Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
COVID-19*
Neoplasms*/drug therapy
Neoplasms*/epidemiology
Aged ; COVID-19 Testing ; Female ; Humans ; Male ; Pandemics ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Autorzy :
Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
Messersmith WA; University of Colorado Cancer Center, Aurora, USA.
Kio EA; Goshen Center for Cancer Care, Goshen, USA.
Berlin JD; Vanderbilt-Ingram Cancer Center, Nashville, USA.
Vahdat L; Weill Cornell Medicine, New York, USA.
Masters GA; Helen F Graham Cancer Center and Research Institute, Newark, USA.
Moroose R; Orlando Health UF Health Cancer Center, Orlando, USA.
Santin AD; Yale University School of Medicine, New Haven, USA.
Kalinsky K; Columbia University Irving Medical Center-Herbert Irving Comprehensive Cancer Center, New York, USA.
Picozzi V; Virginia Mason Cancer Center, Seattle, USA.
O'Shaughnessy J; Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, USA.
Gray JE; H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA.
Komiya T; Parkview Cancer Institute, Fort Wayne, USA.
Lang JM; University of Wisconsin Carbone Cancer Center, Madison, USA.
Chang JC; Houston Methodist Cancer Center, Houston, USA.
Starodub A; Riverside Peninsula Cancer Institute, Newport News, USA.
Goldenberg DM; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Sharkey RM; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Maliakal P; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Hong Q; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Wegener WA; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Goswami T; Immunomedics, Inc., a Subsidiary of Gilead Sciences, Inc., Morris Plains, USA.
Ocean AJ; Weill Cornell Medicine, New York, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 746-756. Date of Electronic Publication: 2021 Mar 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib.
Autorzy :
Citarella F; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy. Electronic address: .
Russano M; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Galletti A; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Vincenzi B; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Tonini G; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Santini D; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 811-813. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Autorzy :
Remon J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
Aldea M; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
Besse B; Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Orsay, France.
Planchard D; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
Reck M; Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Giaccone G; Meyer Cancer Center at Cornell University, New York, USA.
Soria JC; Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Orsay, France; Department of Drug Development, Gustave Roussy, Villejuif, France. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 698-709. Date of Electronic Publication: 2021 Mar 15.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer.
Autorzy :
Tarpgaard LS; Department of Oncology, Odense University Hospital, Odense, Denmark. Electronic address: .
Andersen PV; Department of Surgery, Odense University Hospital, Odense, Denmark.
Øgaard N; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Demuth C; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Andersen CL; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 805-806. Date of Electronic Publication: 2021 Mar 13.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
Raport
Tytuł :
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.
Autorzy :
Vogel A; Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.
Martinelli E; Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
Pokaż więcej
Corporate Authors :
ESMO Guidelines Committee. Electronic address:
ESMO Guidelines Committee
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 801-805. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
Autorzy :
Daveri E; Immunotherapy of Human Tumors Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: .
Luison E; Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Vallacchi V; Immunotherapy of Human Tumors Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Vergani B; School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Leone BE; School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Garassino MC; Medical Oncology Department 1, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan, Italy.
Figini M; Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rivoltini L; Immunotherapy of Human Tumors Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 814-816. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't; Comment
Raport
Tytuł :
The systemic treatment of recurrent ovarian cancer revisited.
Autorzy :
Baert T; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany; Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: .
Ferrero A; Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, Mauriziano Hospital, Turin, Italy.
Sehouli J; Department of Gynecology with Center for Oncological Surgery, Charité-University hospital Berlin, Berlin, Germany.
O'Donnell DM; Department of Oncology, St. James's Hospital, Dublin, Ireland.
González-Martín A; Medical Oncology Department, Clínica Universidad de Navarra University Hospital, Madrid, Spain.
Joly F; Department of Oncology, Centre Francois Baclesse, Caen, France.
van der Velden J; Department of Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
Blecharz P; Department of Gynecologic Oncology, Center of Oncology, M. Sklodowska-Curie Institute, Krakow, Poland.
Tan DSP; Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Querleu D; Department of Surgical Oncology, Institut Bergonié, Bordeaux, France.
Colombo N; Department of Medicine and Surgery, European Institute of Oncology IRCCS, Milan, Italy; University of Milan-Bicocca, Milan, Italy.
du Bois A; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
Ledermann JA; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 710-725. Date of Electronic Publication: 2021 Mar 03.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies